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Abstract
Long-chain Acyl-CoA synthetases (ACSLs) activate fatty acids (FAs) by thioesterification with Coenzyme A (CoA),
generating FA-CoAs. These products are essential for lipid metabolism and carcinogenesis. In previous study, we
identified an intronic variant rs2256368:A>G, whose G allele promotes exon 20 skipping in up to 43% of ACSL5
transcripts but its functional relevance is unclear. Here, we compared the expression of splice (Spl) and nonsplice (NSpl)
ACSL5 variants and the effect on cell viability under culture conditions that force cells to metabolize fatty acids. We
found that lymphoblastoid cell lines from 1000 Genomes Project, bearing Spl genotypes, showed a reduced expression
of total ACSL5 protein due to an inefficient translation of the Spl RNA. These cells impaired growth in cultures with
phorbol myristate acetate-ionomycin (PMA-Io) or medium deprived of glucose, while production of reactive oxygen
species increased in PMA-Io. Specific ACSL5-isoform transfection in HEK239T (kidney), U87 (astroglioma), and HOG
(oligodendrocyte) cells showed the Spl protein to be the causal factor of cell-growth inhibition, despite its reduced
protein expression. Our findings indicate that the variant rs2256368:A>G can predict a growth inhibitory activity, caused
by the Spl isoform of ACSL5 protein, opposed to the activity of the NSpl. Deep understanding of its functioning might
have application in metabolic diseases and cancer.
Introduction
Long-chain acyl-CoA synthetases (ACSLs) activate fatty
acids (FAs: C12-C20), by thioesterification with Coenzyme A
(CoA), generating FA-CoAs. These products are the initial
step in fatty acid metabolism. Once activated, they are
involved in cell growth, differentiation, and energy regulation
[1–5]. Fatty acids physiologically regulate ACSL expression,
but cancer cells could hijack certain involved regulatory
mechanisms to deregulate ACSLs. This deregulation is also
associated with poor survival in patients with cancer [6].
ACSL5 is implicated in several types of cancers and has
a potential prognostic value [6–12]. Unlike other ACSLs,
ACSL5 is downregulated in colorectal carcinomas [13, 14],
breast [10, 15], bladder [15], and pancreas [12]. However,
ACSL5 is overexpressed in glioma [16] and considered a
potential therapeutic target [17–19]. In addition, the fibro-
blast growth factor receptor 2 (FGFR2) ACSL5 chimera
RNA rendered clinical gastric cancer cells resistant to
treatment with FGFR inhibitors [6, 20].
Excess fatty acid metabolism has increasingly been
found to be associated with metabolic disorders and carci-
nogenesis [6]. Genetic variants in ACSL5 may provide a
linkage between the higher prevalence of cancer in obesity.
For instance, ACSL5 rs2419621 T allele carriers are more
responsive to lifestyle interventions partly due to an
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increase in the short ACSL5 protein isoform, increasing
cellular, tissue, and whole-body fatty acid utilization [21].
Also, ACSL5 rs7903146 is one of the most strongly asso-
ciated type 2 diabetes loci and resides within a regulatory
region of an ACSL5 promoter [22].
The G allele of the rs2256368:A>G variant, located at
intron 20 of ACSL5 gene was identify as the cause of exon
20 skipping in up to 43% of transcript molecules, using
expression quantitative trait loci strategy [23]. The present
work characterizes the functional effects promoted by this
splice (Spl) variant. With this end, we compared the
expression of Spl and nonsplice (NSpl) ACSL5 isoforms
and the effect on cell viability in lymphoblastoid cell lines
(LCLs) from 1000 Genomes Project and in other cell lines
from different tissues.
Materials and methods
Nomenclature and database submission
Rs2256368:A>G variant was submitted to the LOVD 3.0/
shared with the submission ID #60251 (http://databases.
lovd.nl/shared/view/ACSL5). This variant (hg19 chr10:
g.114186624G>A) is located in the ACSL5 gene
(NM_016234.3; c.2079+7G>A). The G allele promotes
exon 20 skipping in ACSL5 transcripts (r.2008_2079del)
producing spliced (Spl) ACSL5-Δ20 RNAs [23].
Selection of lymphoblastoid cell lines (LCLs)
Twelve LCLs from HapMap and 1000 Genomes projects,
were purchased from Coriell cell repository (Coriell Institute
for Medical Research, Camden, NJ, USA). These 12 lines
represented the three genotypes of rs2256368:A>G variant:
genotype GG in cell lines HG00134, HG00326, HG01048,
HG01383; genotype AG in lines GM12004, GM12044,
GM12144, GM12717; and genotype AA in lines NA12006,
NA11994, NA12043, NA11993. All cells were cultured in
RPMI+10% FCS as previously described [24].
Relative quantification of RNA in LCLs
ACSL5 RNA concentrations in LCLs were measured by
real-time reverse transcription (RT) qPCR, normalizing the
results to UBE2D2 RNA levels as reported in an earlier
study, using the 2E deltaCt (deltaCt= Ct sample-Ct refer-
ence) method [25]. The primer sequences were (key: for-
ward-Fw; reverse-Rv; E, exon; 5′–3′ direction): UBE2D2
Fw- CAATTCCGAAGAGAATCCACAAGGAATTG and
Rv- GTGTTCCAACAGGACCTGCTGAACAC; non-
spliced (NSpl) E20 ACSL5 (using a bridge E19-E20 to
E21) Fw-CCAAGTTGTAAGGGAAGCCA and Rv-GCTG
TCAATTTGGGTCCGAA; Spl E20 ACSL5 (using bridge
E19-E21 to E21) Fw-ACTGTGCCAAAACCAAGTCA
and Rv- TGTGCTCATACAGGCTGTCA.
Cell extracts
Total cell extracts were acquired using RIPA buffer (50
mMTris-HCl pH 7.4, 150 mMNaCl, 1 mM EDTA, 0.5%
Na-deoxycholates, 0.1% SDS) plus antiproteases from the
Halt Protease Inhibitor Single-Use Cocktail (Pierce,
Rockford, IL, USA). Mitochondrial extracts were isolated
from LCL NA12006E representing genotype AA,
GM12004D representing genotype AG, and HG00134
representing genotype GG, using the Mitochondria Isola-
tion Kit for mammalian cells (Pierce) following the man-
ufacturer’s instructions and using RIPA buffer for protein
extraction.
Western blots
Cell extracts in RIPA buffer were processed for protein
separation by sodium-dodecyl sulfate-7% polyacrylamide
gel electrophoresis (SDS-PAGE) under reducing conditions
and transferred to Immobilon-P transfer membranes
(Merck-Millipore Ltd., Cork, Ireland). Blots were incubated
with different antibodies from Abcam (Abcam plc, Cam-
bridge, UK). As primary antibodies we used anti-ACSL5
(ab57210) and anti-V5 tag (ab27671); as a secondary anti-
body, a horseradish peroxidase (HRP)-labeled anti-mouse
IgG (ab97023) was used. As a loading control, we used an
anti-beta Actin-HRP- labeled antibody (Ab8226) following
conditions indicated by the manufactures. Protein bands
were detected by an enhanced chemiluminescent substrate
for detection of HRP using Pierce ECL Western Blotting
Substrate (ThermoScientific, Rockford, IL, USA).
ACSL5 protein quantification in LCLs
Relative expression of ACSL5 protein was determined by
band densitometry of the signal generated on a western blot
film, using Bio-Rad’s Image Lab Software (Bio-Rad
Laboratories, Hercules, California, USA) as indicated in
Supplementary Methods. The band densitometry results
were normalized twice: (1) against beta-actin; and (2)
against the highest concentration of ACSL5 protein.
Cell viability of LCLs
The 12 LCLs were cultured at 2500 cells per well in 96-well
microtiter plates in three different culture conditions: (i)
control cultures (CTL) with the usual growing media
indicated above; (ii) cultures treated with phorbol myristate
acetate-ionomycin (PMA-Io) [50 ng/ml of phorbol
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12-myristate 13-acetate (PMA) plus 10 ng/ml Ionomycin
(Io) [Sigma Aldrich, Madrid, Spain]); and (iii) glucose-
depleted culture media (no glucose) plus 10% FCS. Growth
measurements were performed at 6, 24, and 48 h of culture.
Cell viability was determined using the Cell-Titer-Glo
Luminescent Cell Viability Kit (Promega, Madison, WI,
USA). All readings were first normalized with the readings
at 6 h (growth index) and then, the relative growth of each
LCL in PMA-Io-treated media or in glucose depleted cul-
tures, were normalized to the growth index of the CTL
cultures (relative growth index). Each time point shows the
mean growth of four LCLs with the same genotype, and the
standard error of mean (+/-SEM). Each experiment was
performed five times for each condition in 12 replicates.
ROS production in LCLs
ROS production was measured in the 12 LCLs cultured in
media treated with PMA-Io, seeded at 5000 cells per well in
96-well microplates for 0.5, 2, 4, and 6 h, using the Cellular
Reactive Oxygen Species Detection Assay Kit (Abcam,
ab113851), following the manufacturer’s instructions. This kit
uses the cell permeant reagent 2′,7′-dichlorofluorescin diacetate
(DCFDA) to measure ROS activity within the cell. The
resulting oxidation of DCFDA by intracellular ROS was
detected by fluorescence spectroscopy with an Infiniti®Lumi
Microplate Reader (Tecan, Mannedorf, Switzerland) with
maximum excitation and emission spectra of 495 and 529 nm,
respectively.
Cloning of ACSL5 isoforms
RNA from one LCL bearing rs2256368 GG genotype,
which produced about 60% NSpl and 40% Spl ACSL5
transcripts, was reverse-transcribed (RT) [23]. The cDNA
was amplified by PCR using the following primers (in
bold is the linker for directional cloning): Fw-CAC-
CAGCACGTTAGAAAGCCTGAC and Rv-ATCCTG-
GATGTGCTCATACA, with the Q5 High-Fidelity DNA
Polymerase Kit (New England BioLab, Ipswich, MA,
USA), in the following PCR conditions: 1 cycle of 94 °C
for 3 min; 34 cycles of 94 °C for 30 s; 60 °C for 30 s; 72 °C
for 2 min. The PCR products were cloned into the
expression plasmid pcDNA6.2/GW/D-TOPO (Invitrogen,
Carlsbad, CA, USA). The resulting plasmid inserts were
amplified by PCR from E19 of ACSL5 to the V5
tag sequence in the plasmid using primers: ACSL5
exon (E)19 Fw-CTTCCCTCATTTGCAGCCAA and V5
Rv- CCTAACCCTCTCCTCGGTCT. The PCR conditions
were: 1 cycle of 94 °C for 3 min, followed by 34 cycles of
94 °C for 20 s, 60 °C for 20 s, plus 72 °C for 1 min. The
plasmids DNAs were validated by Sanger sequencing and
purified with an EndoFree Plasmid Maxi Kit (QIAGEN
GmbH, Hilden, Germany) for transfection experiments.
Transfection of different cell lines with ACSL5
isoforms
HEK293 (human embryonic kidney [epithelial]), U87MG
(human brain [astroglioma]), and HOG (human oligoden-
drocyte) [26] cell lines were cultured in DMEM medium
(low glucose for HEK) supplemented with 15% fetal calf
serum and 100 U/ml penicillin/streptomycin (all from
Gibco, Invitrogen. Carlsbad, CA, USA). In all 0.5 × 106
cells/well were seeded on a six-well plate, and transfected
with the different recombinant plasmids using lipofectamine
LTX reagent (Invitrogen) following the manufacturer’s
instructions. The expression of ACSL5 mRNA and ACSL5
protein was analyzed at different times post-transfection,
contemplating 48 h post transfection as optimal (determined
in preliminary experiments).
Absolute RNA quantification by digital PCR
RNA was purified from transfected HEK293 cells using the
RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) and reverse
transcribed into cDNA using Superscript III First-Strand
Synthesis SuperMix (Invitrogen) [26]. Expression of ACSL5-
V5 mRNA levels was subjected to absolute quantification by
droplet digital qPCR (ddqPCR) using QX200 ddPCR Eva
Green Supermix and QuantaSoft software (Bio-Rad).
The PCR amplification of the NSpl ACSL5-V5 construct
was performed using a bridge primer that hybridizes with
sequences in exons 19−20 (Fw-ACTGTGCCAAAAC
CAAGTTG) and with the sequence of the V5 tag (Rv-
AGACCGAGGAGAGGGTTAGG). The PCR amplification
for the Spl ACSL5-V5 construct (ACSL5Δ20-V5), was per-
formed using a bridge primer that hybridizes with sequences
in exons 19−21 (Fw-ACTGTGCCAAAACCAAGTCA), and
with the sequence of the V5 tag (Rv), as indicated above.
Cell viability of cell lines transfected with ACSL5
isoforms
HEK293, U87MG, and HOG cell lines, transfected with
the ACSL5 isoforms, were seeded at 2,500 cells per well
in 96-well microtiter plates, at 48 h post transfection. Cell
viability was determined using the Cell-Titer-Glo Lumi-
nescent Cell Viability Kit (Promega, Madison, WI, USA)
following manufacturer’s instructions. Luminescence was
measured using Infinite®Lumi Microplate Reader (Tecan).
The readings at 24 are indicated versus the readings at 6 h.
Each experiment was performed three times in 12
replicates.
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Statistical analysis
Statistical analysis was performed with RStudio software.
Values are shown as mean ± SEM and the number of
independent experiments (n) performed are indicated above.
Data were analyzed by Pearson’s correlation or ANOVA
and Bonferroni post-hoc test. A value of p < 0.05 was set as
the limit of statistical significance.
Results
ACSL5 isoforms
ACSL5 expresses three major transcript isoforms, though
only two full-length proteins have been usually observed [1].
Two of them have two in-frame AUG-translational initiators
that produce isoforms of different length (Fig. 1a). The longer
product (L) is initiated at the first AUG codon, AUG1, cor-
responding with variant 1. A shorter product (S) is initiated at
the downstream AUG2 (v3). A third variant is generated by
alternative splicing of the penultimate exon of ACSL5, cor-
responding with variant v2 (Spl). This Spl isoform is pro-
moted by the genetic variant rs2256368:A>G [23].
ACSL5 isoforms expressed in LCLs
In order to check the expression of major ACSL5 protein
isoforms in LCLs, a western blot of extracts from cells
expressing representative % of Spl and NSpl RNAs, with an
anti-ACSL5 antibody, was performed (Fig. 1b). Results
showed similar band profiles in the three genotypes. How-
ever, the Spl-protein bands, with 3.7 kDa less than the L and
S isoforms, were not observed. GG-bearing cells, which
expressed 40% of SplRNA, showed an important decrease
in total ACSL5 protein.
Expression analysis of RNA and protein isoforms
versus genotypes
For the purpose of finding an explanation to the previous
observations, we carried out an expression analysis of RNA
and protein isoform levels in 12 LCLs, four of each genotype
(Fig. 2). For instance, the LCL no. 10, carrier of GG geno-
type, produced 43% of Spl RNA (Fig. 2a), but the Spl protein
was not apparently detected (Fig. 2b). The correlation analysis
showed that the increase of Spl RNA, and the G-allele doses,
was linked to the decrease of total ACSL5 protein (Fig. 2c).
The high determination coefficient (r2= 0.69) suggested that
the major part of the ACSL5 protein reduction corresponded
to the increase of Spl RNA (Fig. 2d). All of these data sug-
gested that the expression of Spl-ACSL5 protein was down-
regulated as compared to the NSpl isoforms.
Ectopic expression of Spl and NSpl isoforms
To elucidate if the SplRNA was translated into protein,
HEK293 cells were transfected with the Spl and NSpl
cDNA constructs. The results showed that the both RNA
isoforms, Spl and NSpl, were expressed similarly in the
corresponding transfected cells (Fig. 3a). However, a dra-
matic decrease of Spl-protein levels was observed, without
signs of differential degradation. Thus, these data suggested
that the Spl-RNA was translated into protein in a
very inefficient way, compared to the NSpl-isoform. In
addition, these data explained why the Spl protein, endo-
genously expressed in LCLs bearing GG genotypes, was
not detected.
Cell viability of LCL bearing Spl and NSpl genotypes
Given the implications of ACSL5 in mitochondrial
functions, we measured the ATP content (correlating with
cell growth) in the 12 LCLs bearing the three rs2256368:
A>G genotypes (Fig. 4), under mitochondrial-related
stress conditions. Thus, cells were cultured in culture
media with PMA-Io, stimulating lymphocyte cell growth
[25] (Fig. 4a), which increased the mitochondrial func-
tion; or in culture media depleted of glucose, called
“No glucose” in the figure (Fig. 4b), forcing cells to use
exogenous long-chain fatty acids as energy source.
Growth of each treated culture was referred to the growth
at 6 h and then to the corresponding untreated culture
(relative growth index). Cells bearing AA genotype, sti-
mulated with PMA-Io, responded increasing growth more
Fig. 1 Expression of ACSL5 protein isoforms in LCLs.
a ACSL5 scheme representing the major protein isoforms. b Western
blots of mitochondrial (mit) extracts from LCLs bearing the three
rs2256368:A>G genotypes (AA, AG, GG) loaded at different con-
centrations (1X, 1.5X and 2X). The three LCLs expressed different
proportions of Spl RNA respect to the NSpl one (AA— 1.8%, AG—
14%, and GG—43%). Molecular weights of ACSL5 L and S were
calculated from the amino acid sequence
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than the untreated cells and were not affected by
absence of glucose within 48 h of culture, compared with
standard medium with glucose and without PMA-Io. By
contrary, cells bearing AG or GG genotypes were sig-
nificantly affected, reducing the growth under PMA-Io
stimulation, and in cultures depleted of glucose, respect
to the control cultures. These findings suggested an
association of the impaired cell growth capability with
the G allele carriers under mitochondrial stress. Thus,
expression of the SpL protein and/or decrease of total
ACSL5 protein were the two variables associated with
these growth effects.
Reactive oxygen species
To assess whether the impaired cell growth of LCLs bearing
the G allele was related with the oxidative stress response,
cells were stimulated with PMA-Io up to 6 h. Treatment
with PMA-Io resulted in ROS production, which was
always higher in cells expressing the Spl variant (GG
bearing cells). The results were normalized to the positive
control treatment, using tert-Butyl hydroperoxide (Fig. 4c).
All these data suggested that the cells containing the
rs2256368 G allele were negatively affected when
mitochondrial-related stressors were present.
Fig. 2 Analysis of ACSL5 expression in LCLs. a Quantification of
RNA isoforms in 12 LCLs. This panel has been previously published
by Matesanz et al. [23], licensed under a Creative Commons
Attribution-NonCommercial-ShareAlike 4.0 International License,
http://creativecommons.org/licenses/by-nc-sa/4.0/. The panels show
end-point PCR amplification visualized in polyacrylamide gel elec-
trophoresis and, additionally, quantified by relative real-time qPCR:
(top) Nonspliced ACSL5 transcripts (NSpl); (bottom) spliced ACSL5
transcripts (Spl). b Western blots with an anti-ACSL5 antibody of the
same LCLs as in the RNA panel. An anti-beta-actin HRP-labeled
antibody was used as a loading control for relative protein quantifi-
cation (“Materials and methods” and Supplementary Material S1).
c Plot representing relative expression levels of ACSL5 protein (L+S)
(white bars) and ratio of Spl versus NSpl RNAs (dark bars). d Cor-
relation plot of Spl to NSpl RNA ratios versus relative ACSL5 protein
levels. Pearson correlation was used to estimate determination coeffi-
cient (R2) and P-value
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Identification of causal isoform of the growth
inhibition
Finally, to identify the ACSL5 isoform responsible for the
growth inhibition, different cell lines (HEK293, U87, and
HOG) were transfected with the different ACSL5 constructs
(Fig. 5a). Thus, the cells transfected with the Spl construct
(pSpl-V5) showed lower growth capability than the control
cultures transfected with the plasmid (p-v5), as opposed to
the growth capability of cells transfected with the NSpl
construct (pNSpl-V5). Therefore, despite its low produc-
tion, the Spl-V5 protein impaired cell growth in comparison
to the NSpl-V5 and p-V5. On the other hand, ROS pro-
duction (data not shown) was increased in all of these cell
lines expressing recombinant Spl-V5 protein, but with no
statistical significance, except U87 cells. This could happen
because the induction times of ROS and the expression of
the cDNA-V5 constructs did not coincide (data not shown).
All these cells expressed the ACSL5 constructs in a similar
way as shown in transfected HEK293 in Fig. 3b, but HOG
cells expressed a higher ratio of Spl-V5 protein to NSpl-V5
(data not shown). Basal expression of RNA and protein was
detected neither in HEK293 nor in U87. However, HOG cells
expressed a minimal amount of RNA and protein (Fig. 5b, c).
Discussion
This study aimed at analyzing the functional role of the
genetic variant rs2256368:A>G whose G allele promotes
exon 20 skipping in up to 43% of ACSL5 transcripts [23].
We found that the Spl RNAs were translated into Spl pro-
teins very inefficiently, as compared with the translation
levels of the NSpl isoforms.
The differential production of Spl and NSpl proteins was
clearly observed in LCLs bearing GG genotype, expressing
Fig. 3 Expression analysis of Spl and NSpl constructs in transfected
HEK293 cells. a Droplet digital PCR quantification of RNA expres-
sion from the spliced (pSpl) and nonspliced (pNSpl) cDNAs, visua-
lized in agarose-gel electrophoresis. Ctl-1 and Ctl-2 were PCR
negative controls (RT performed without RT enzyme) for each iso-
form. Lane m was loaded with a DNA size marker mix (Marker V
from Roche). b ACSL5 protein expression analysed by western blots
of extracts from the transfected cells. Lane LCL is a positive control
extract containing endogenous ACSL5 from one LCL, for comparison
with the recombinant constructs from transfected cells. Lane kDa
represents the position of molecular size markers. Letters and lines
inside the blots are explained on the right site, representing the protein
sequence-calculated molecular weights of the different ACSL5 mole-
cules detected
Fig. 4 Relative growth index of 12 LCLs, four of each rs2256368:
A>G genotype. Cells were cultured under conditions that force cells to
use long-chain fatty acids and compared with the growth in control
cultures. Student t-test was used to estimate difference between each
genotype group. P-values (P) at 48 h of culture were in a P(AA versus
AG)= 0.0487; P(AG versus GG)= 0.0013; P(AA versus GG)
<0.0001. b P(AA versus AG)= 0.0095; P(AG versus GG)= 0.463;
P(AA versus GG)= 0.0003. c Relative ROS production of the 12
LCLs in presence of PMA-Io
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both RNA isoforms, as well as in cell lines transfected with
the two cDNA constructs. In this last case, the Splprotein
expression was drastically reduced compared with the NSpl
isoform, from similar number of corresponding mRNA
molecules. Consequently, one or several mechanisms of
translation regulation, that take place in the cell, might be
affecting the production of the Spl protein.
It has been described microRNAs (miRNAs) that block
the translation initiation without detectable changes in
mRNA levels [27, 28]. For the more highly repressed
mRNA translation, its destabilization explains most miRNA-
mediated repression [29]. Another possible mechanism
could be based on the cell quality control, preventing
synthesis of aberrant Spl proteins at the ribosome [30, 31].
Aberrant, misfolded, and mislocalized proteins are often
toxic to cells and result in many human diseases. Although
this mechanism could also affect the Spl protein, we did not
observe evidence of specific differential degradation.
We showed that the Spl protein was responsible of the
growth-inhibitory effect, despite its low protein expression.
The evidence were obtained from LCLs expressing the Spl
isoform, cultured in conditions that forced cells to use long-
chain fatty acids, as well as from cell lines transfected with
the two ACSL5 isoforms. In both cases, the growth-
inhibitory effect caused by the Spl protein was opposed to
the growth-promoting activity of the NSpl isoform, inhi-
biting cell growth below the level of control cells. These
results suggested that the activity of the Spl protein had a
certain toxic effect, which would be attenuated by ineffi-
cient translation of the Spl variant. Using a conceptual
explanation from Battle et al. [32], it seems that this “det-
rimental” impact on cell growth is being attenuated or
buffered by a large reduction of protein production
[30, 32, 33]. In addition, our data also support that NSpl
ACSL5 levels may be essential to reduce ROS-related
stress, driving to a correct cell growth.
A detrimental alternative splicing that involves exon
7 skipping in the SP140 transcripts has also been reported
[34, 35]. The genetic variant that promotes this alternative
splicing is associated with multiple sclerosis, Crohn’s dis-
ease, and chronic lymphocytic leukemia. However, what
associates with the indicated diseases is the reduction of the
NSpl protein expression because the Spl protein variant was
not expressed.
Exon 20 skipped variant of ACSL5 protein (Spl) was
studied for the first time by Gassler et al. [36]. They
revealed that the ratio of the ACSL5-full length and the Spl-
ACSL5 protein increases along the crypt-villus axis of
human small intestine. This fact was considered of func-
tional relevance for apoptosis of senescent enterocytes at the
villus tip and suggested to be involved in the pathogenesis
of several intestinal disorders such as intestinal neoplasia
[36]. It is unknown if the Spl ACSL5 isoform was promoted
or not by the genetic variant analyzed in this study. Given
that ACSL5 is highly expressed in human small intestinal
mucosa, it would be possible that a small amount of the
transcript is Spl even in the nonsplicing genotype AA.
The different allelic carriers of this genetic variant may
produce large differences in the expression of the Spl
transcripts (expression quantitative trait loci, eQTL) and
protein isoforms (protein quantitative trait loci, pQTL),
thereby it can increase phenotypic variability and the sus-
ceptibility to complex traits in human populations
[30, 33, 37, 38]. Future association studies are necessary to
find conditions in which this variant is involved.
As a marker, this genetic variant may be useful to predict
the presence of an Spl RNA besides of the corresponding
Spl protein. Its low expression level seems to attenuate its
strong growth-inhibition effect. ACSL5 is generally
decreased in those cancer types where ACSL1 and ACSL4
are upregulated [6], so it would be interesting to deepen our
understanding of the mechanisms implicated in this alter-
native splicing, because it seems that between both isoforms
there is a potential response against the two type of
cancer cells, the ones that upregulate ACSL5 and the ones
that downregulate it. All of these results may be of
Fig. 5 Effect of ACSL5 isoforms on cell viability. a Growth index of
cells transfected with control plasmid (p-V5), nonspliced (pNSpl-V5)
and spliced (pSpl-V5) constructs. Statistical significance is indicated
with asterisks: *P < 0.05; **P < 0.005; ***P < 0.0005. b Basal level of
ACSL5 RNA in nontransfected cells. One LCL is included to show the
endogenous expression of Spl and NSpl isoforms, as a positive con-
trol. These data were obtained by real time qPCR and the amplified
samples were run in a polyacrylamide gel electrophoresis. UBE2D2
expression was used as a reference. c Basal level of ACSL5 protein
expression performed by western blots of nontransfected cell lines
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relevance in conditions involving lipid metabolism and
carcinogenesis.
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